Not surprisingly Bioshares has put Opthea in it’s Xmas stocking as one of its 6 stock picks for 2019. Citing the company’s exceptional progress with trials this year it sees the company as being a standout investment at current prices. In addition it sees OPT-302 as having a competive advantage due to it being one of the very few drugs to target both wet AMD and DME. One further comment was the potential for a high value transaction to take place in 2020 pending positive and convincing results from both trials.
Merry Xmas everyone.
Ann: Becoming a substantial holder, page-5
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
78.0¢ |
Change
-0.010(1.27%) |
Mkt cap ! $960.2M | |||
| Open | High | Low | Value | Volume |
| 79.0¢ | 79.5¢ | 74.5¢ | $2.420M | 3.109M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | 77.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 78.0¢ | 77447 | 1 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| OPT (ASX) Chart |